GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE1943.1061.4 (+3.26 %)
PREV CLOSE ( ) 1881.70
OPEN PRICE ( ) 1888.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18731
TODAY'S LOW / HIGH ( )1888.45 1963.15
52 WK LOW / HIGH ( )1228 2649.95
NSE1946.6066.8 (+3.55 %)
PREV CLOSE( ) 1879.80
OPEN PRICE ( ) 1890.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1946.60 (91)
VOLUME 120032
TODAY'S LOW / HIGH( ) 1890.45 1962.35
52 WK LOW / HIGH ( )1227 2524
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 13-11 1924
Management Info
R S Karnad - Chairman Bhushan Akshikar - Managing Director
Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
13Mar Glaxosmithkline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
06Mar GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
27Feb Glaxosmithkline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
23Feb GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
21Feb Glaxosmithkline Pharmaceuticals inform
Glaxosmithkline Pharmaceuticals has informed that pursuant to Regulation..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit454.9000000000016077.5
Gross Profit 651.100000000001 8323.8
Operating Profit 2458.59009.3
Net Sales 8049.832163.4
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap (Rs. in Cr)57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap (Rs. in Cr)18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap (Rs. in Cr)102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap (Rs. in Cr)91234.91
RPG Life Sciences (BSE)
 1530.20 (3.92%)
M.Cap (Rs. in Cr)2530.80
Shareholding Pattern
PROMOTERS 75%
NON-INSTITUTION 13.43%
MUTUAL FUNDS/UTI 4.5%
FI/BANKS/INSURANCE 4.04%
GOVERNMENT 0.01%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.